Cardiotoxicity of Anti-Cancer Radiation Therapy: a Focus on Heart Failure.

Cardio-oncology Cardiotoxicity Heart failure Radiation therapy Thoracic malignancies

Journal

Current heart failure reports
ISSN: 1546-9549
Titre abrégé: Curr Heart Fail Rep
Pays: United States
ID NLM: 101196487

Informations de publication

Date de publication:
02 2023
Historique:
accepted: 06 12 2022
pubmed: 25 1 2023
medline: 4 3 2023
entrez: 24 1 2023
Statut: ppublish

Résumé

As the percentage of patients achieving long-term survival following treatment of their cancer grows, it is increasingly important to understand the long-term toxicities of cancer-directed treatment. In this review, we highlight the recent findings regarding radiation-induced cardiotoxicity across multiple disease sites, with a particular focus on heart failure. Despite its relative lack of study historically, radiation-induced heart failure has now recently been implicated in several studies of breast cancer, lung cancer, esophageal cancer, and lymphoma as a non-trivial potential consequence of thoracic radiotherapy. Data regarding specific cardiac dosimetric endpoints relevant to cardiotoxicity continue to accumulate. Radiation-induced heart failure is a rare but significant toxicity of thoracic radiotherapy, that is likely underreported. Important areas for future focus include understanding the interplay between thoracic radiotherapy and concurrent cardiotoxic systemic therapy as well as development of potential mitigation strategies and novel therapeutics.

Identifiants

pubmed: 36692820
doi: 10.1007/s11897-023-00587-0
pii: 10.1007/s11897-023-00587-0
doi:

Types de publication

Journal Article Review Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

44-55

Subventions

Organisme : NHLBI NIH HHS
ID : L30 HL149063
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016058
Pays : United States
Organisme : NHLBI NIH HHS
ID : K23 HL155890
Pays : United States

Informations de copyright

© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Auteurs

Alex Ritter (A)

Department of Radiation Oncology, The Ohio State University Comprehensive Cancer Center, OH, Columbus, USA.

Cooper Quartermaine (C)

Cardio-Oncology Program, Division of Cardiology, The Ohio State University Medical Center, Columbus, OH, USA.

Jovan Pierre-Charles (J)

Cardio-Oncology Program, Division of Cardiology, The Ohio State University Medical Center, Columbus, OH, USA.

Suryakumar Balasubramanian (S)

Cardio-Oncology Program, Division of Cardiology, The Ohio State University Medical Center, Columbus, OH, USA.
Velammal Medical College Hospital & Research Institute, Madurai, India.

Pejman Raeisi-Giglou (P)

Cardio-Oncology Program, Division of Cardiology, The Ohio State University Medical Center, Columbus, OH, USA.

Daniel Addison (D)

Cardio-Oncology Program, Division of Cardiology, The Ohio State University Medical Center, Columbus, OH, USA.
Division of Cancer Control, James Cancer Hospital and Solove Research Institute at The Ohio State University, Columbus, OH, USA.

Eric Miller (E)

Department of Radiation Oncology, The Ohio State University Comprehensive Cancer Center, OH, Columbus, USA. Eric.Miller@osumc.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH